Pfizer to Cut $3.5B in Costs, Close NJ Plant

There was a time when the world was heavy with anticipation for COVID vaccines and boosters — to the point where desperate consumers were lining up for their chance for an inoculation that was tantamount, for many, to a “get out of quarantine free card.”

But three years past the initial panic of the COVID-19 pandemic, and two years into mass vaccinations, things have stabilized. And while most of it is good for humankind, pharma companies at the forefront of these solutions are now facing some sluggish demand.